Rapid Onset and Fatal Outcome of Two Squamous Cell Carcinomas of the Genitalia in a Patient Treated with Etanercept for Cutaneous Psoriasis

Christelle Comte, Jean-Jacques Guilhou, Bernard Guillot, Olivier Dereure
Department of Dermatology, Hôpital Saint-Eloi, University of Montpellier, Montpellier, France

Key Words
Etanercept · Penis · Squamous cell carcinoma, metastasis

The hazard of developing skin or mucous membrane tumors during anti-TNF-α treatment remains a debated topic but large-scale cohort surveys did not substantiate this possibility so far for rheumatoid arthritis and Wegener’s granulomatosis patients despite alarming, though individual reports [1–3]. However, the more recent use of these therapeutics in psoriasis patients raises this question in more critical terms due to the previous use in this subset of patients of immunosuppressive or potentially carcinogenic therapies such as phototherapy, methotrexate, ciclosporine or coal tar, as illustrated by the rapid onset of penile cutaneous squamous cell carcinoma (SCC) in a patient receiving etanercept for psoriasis [4]. We hereby report on a similar observation emphasizing this potential risk.

A 71-year-old patient without any other significant medical background had been treated for more than 30 years for a widespread cutaneous psoriasis with several topical treatments, phototherapy (PUVA and UVB with protection of the genitals for the most recent treatments) and systemic drugs (retinoids, ciclosporine, methotrexate, salazopyrine and eventually etanercept 25 mg twice a week with a good clinical result). A first cutaneous epidermoid carcinoma was diagnosed on the right thigh in 1994 with no subsequent relapse. Thirty-four months after etanercept had been introduced, 2 nodular and infiltrated lesions of the penile and the scrotal area of 5 and 15 mm in diameter, respectively, appeared almost simultaneously and rapidly grew in size. No regional lymph node enlargement was initially present. Histological examination of both lesions disclosed an ill-differentiated infiltrating SCC. A search for HPV infection using in situ hybridization and specific PCR was conducted on both lesions and proved negative. Clinical and morphological staging was unremarkable, and both lesions were surgically removed with a 1-cm margin. Etanercept was interrupted but a large metastatic inguinal lymph node developed 9 months after primary tumor excision. A complete inguinal dissection was then carried out after tumoral reduction by chemotherapy with carboplatin and gemcitabine. Three months after regional surgery, metastatic lymph nodes of the same location progressively recurred with invasion of the femoral vein; the patient finally died 16 months after the initial diagnosis.

Anti-TNF-α agents durably inhibit the development of the cytotoxic T-cell response which plays a central role in tumor promotion and progression control and this biological effect might increase the hazard of malignancy or the aggressivity of tumors as a consequence. In this perspective, the report of 7 cutaneous SCCs of rapid onset in 5 rheumatoid arthritis patients receiving etanercept for a limited period of time was initially worrisome regarding a higher risk of cutaneous tumors, but no additional case was reported since then with the noticeable exception of a penile SCC in a patient receiving etanercept for psoriasis [4]. However, previous exposure to high doses of UVA or UVB and/or to other immunosuppressive agents such as ciclosporine for psoriasis probably delineates a special subset of patients at higher risk of developing SCC when compared to other indications such as rheumatoid arthritis, the genital area being perhaps the more significant target as already reported in psoriasis [5] and as illustrated both by our observation and by the report of Fryrear et al. [4]. The hypothesis of a previous but latent infection by oncogenic strains of HPV can be raised as well since the onset of genital HPV lesions occurring in patients receiving anti-TNF-α agents has recently been reported [6]; however, no clue for the presence of HPV sequences was present in our patient. The delay between anti-TNF-α introduction and the occurrence of genital mucous membrane SCC was longer in both patients than in the report of Smith and Skelton [3] but not inconsistent with the usual process of carcinogenesis. Owing to the pharmacological profile of these molecules, other clinical features might be more frequent in anti-TNF-α-associated cutaneous SCC such as multiple tumors, rapid local growth and perhaps a higher metastatic potential, all characteristics featured by our patient. On the other hand, it is of interest to note that the use of efalizumab, another non-anti-TNF-α biological agent currently used in psoriasis, has not been linked to a significant increase in the patients’ risk of developing skin malignancies [7] although the occurrence of multiple dermatofibromas, a cutaneous condition sometimes also related to immunodeficiency, has recently been reported in this therapeutic setting [8]. Although definitive conclusions cannot be drawn on so few cases, a very careful examination of the whole body surface including the genitals must be carried out on a regular basis in psoriasis patients receiving anti-TNF-α agents. Furthermore, the patient’s background must be carefully checked before considering anti-TNF-α treatment, and a history of skin carcinoma might B.G. is currently involved in a clinical study using infliximab (Remicade®, Schering-Plough).
represent a serious limitation. Additionally, restricting the pre-
scription of anti-TNF-α agents to patients who have always re-
ceived maximal doses of phototherapy is perhaps not entirely ad-
equate; should such observations become relevant in the future,
they might lead to reconsidering the recommendations of anti-
TNF-α usage as a last-line therapy.

References

1 Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, Wallis
WJ: No evidence for increased risk of cutaneous squamous cell carci-
noma in patients with rheumatoid arthritis receiving etanercept for up
2 Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min
YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ,
Ytterberg SR, Allen NB, Hoffman GS, Wegener’s Granulomatosis
Etanercept Trial Research Group: Solid malignancies among patients
in the Wegener’s Granulomatosis Etanercept Trial. Arthritis Rheum
2006;54:1608–1618.
3 Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carci-
noma in patients with rheumatoid arthritis after starting tumor necro-
sis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad
4 Fryrear RS 2nd, Wiggins AK, Sanguez R, Yosipovitch G: Rapid onset
of cutaneous squamous cell carcinoma of the penis in a patient with
5 Stern RS, Bagheri S, Nichols K, PUVA Follow-Up Study: The persistent
risk of genital tumors among men treated with psoralen plus ultravio-
6 Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD: Genital
HPV lesions and molluscum contagiosum occurring in patients receiv-
7 Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P,
Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies
observed during efalizumab (Raptiva) clinical trials for plaque psoria-
8 Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J: Multiple
eruptive dermatofibromas in a patient receiving efalizumab. Derma-
tology 2008;216:363.

O. Dereure
Department of Dermatology, University Hospital of Montpellier
Hôpital Saint-Eloi, 80, avenue A. Fliche
FR-34295 Montpellier Cedex 5 (France)
Tel. +33 467 33 69 06, Fax +33 467 33 69 58
E-Mail o-dereure@chu-montpellier.fr